TY - JOUR
T1 - Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension
T2 - State of the art and considerations for the future
AU - Mahfoud, Felix
AU - Schmieder, Roland E.
AU - Azizi, Michel
AU - Pathak, Atul
AU - Sievert, Horst
AU - Tsioufis, Costas
AU - Zeller, Thomas
AU - Bertog, Stefan
AU - Blankestijn, Peter J.
AU - Böhm, Michael
AU - Burnier, Michel
AU - Chatellier, Gilles
AU - Zaleski, Isabelle Durand
AU - Ewen, Sebastian
AU - Grassi, Guido
AU - Joner, Michael
AU - Kjeldsen, Sverre E.
AU - Lobo, Melvin D.
AU - Lotan, Chaim
AU - Lüscher, Thomas Felix
AU - Parati, Gianfranco
AU - Rossignol, Patrick
AU - Ruilope, Luis
AU - Sharif, Faisal
AU - Van Leeuwen, Evert
AU - Volpe, Massimo
AU - Windecker, Stephan
AU - Witkowski, Adam
AU - Wijns, William
N1 - Funding Information:
S.E.K. is supported by the Norwegian Government and the Norwegian Council for Cardiovascular Diseases, and has received speaker honoraria and consultancy fees from ABDiiBRAHiM, Bayer, MSD and Takeda within the past 3 years.
Funding Information:
... Funding ... The European Expert meeting was supported by an unrestricted educa- ... tional from Europa Organisation, Toulouse, France. ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...
Funding Information:
M.D.L. is supported by the Barts Charity and has received speaker honoraria and consultancy fees from CVRx, St Jude Medical, ROX Medical and Cardiosonic. C.L. has received consultancy fees from Medtronic.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - The interest in RDN for hypertension has fluctuated recently, with a flurry of initial enthusiasm followed by sudden loss of interest by researchers and device manufacturers, with an almost as sudden resurgence in clinical trials activity and device innovation more recently. There is widespread consensus that this therapeutic strategy can be effective, at least for some of the technologies available. Major uncertainties remain as to the clinical role of RDN, and whether any of the emerging technologies such as AV-anastomosis formation, carotid body ablation, carotid bulb expansion, or baroreflex stimulation will have a future as effective treatment options in patients with hypertension. In our first consensus report in 2015, the European Expert Group pointed to the major unmet need of standardization of measurements, trial design and procedural performance.6 With the large number of different technologies currently in the pipeline, this need has even increased. Only through high-quality, collaborative research and openness to new methods for recruitment, patient selection, and assessment of outcomes will it be possible to establish incontrovertibly whether device therapies for hypertension are effective and what are preferred patient populations. Once the proof of concept is established, further studies with a design relevant to clinical reality will be needed to establish the place of new devices in the treatment armoury. The clinical and research community has a large responsibility to prove or disprove the value of new therapies, in order to ensure that antihypertensive devices provide future patients with the greatest benefit and the smallest risk. copy; The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology.
AB - The interest in RDN for hypertension has fluctuated recently, with a flurry of initial enthusiasm followed by sudden loss of interest by researchers and device manufacturers, with an almost as sudden resurgence in clinical trials activity and device innovation more recently. There is widespread consensus that this therapeutic strategy can be effective, at least for some of the technologies available. Major uncertainties remain as to the clinical role of RDN, and whether any of the emerging technologies such as AV-anastomosis formation, carotid body ablation, carotid bulb expansion, or baroreflex stimulation will have a future as effective treatment options in patients with hypertension. In our first consensus report in 2015, the European Expert Group pointed to the major unmet need of standardization of measurements, trial design and procedural performance.6 With the large number of different technologies currently in the pipeline, this need has even increased. Only through high-quality, collaborative research and openness to new methods for recruitment, patient selection, and assessment of outcomes will it be possible to establish incontrovertibly whether device therapies for hypertension are effective and what are preferred patient populations. Once the proof of concept is established, further studies with a design relevant to clinical reality will be needed to establish the place of new devices in the treatment armoury. The clinical and research community has a large responsibility to prove or disprove the value of new therapies, in order to ensure that antihypertensive devices provide future patients with the greatest benefit and the smallest risk. copy; The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology.
UR - http://www.scopus.com/inward/record.url?scp=85021253377&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehx215
DO - 10.1093/eurheartj/ehx215
M3 - Review article
C2 - 28475773
SN - 0195-668X
VL - 38
SP - 3272-3281a
JO - European Heart Journal
JF - European Heart Journal
IS - 44
ER -